Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:FOLDNASDAQ:LGNDNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsFOLDAmicus Therapeutics$5.71$6.34$5.58▼$12.65$1.76B0.543.07 million shs4.00 million shsLGNDLigand Pharmaceuticals$118.22+2.8%$107.09$77.53▼$129.90$2.22B0.83117,600 shs135,249 shsMNKDMannKind$3.99+5.0%$4.37$3.63▼$7.63$1.15B1.022.38 million shs3.52 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%FOLDAmicus Therapeutics0.00%-1.55%-8.20%-32.98%-42.90%LGNDLigand Pharmaceuticals+2.83%+5.05%+16.36%+9.37%+47.85%MNKDMannKind+5.00%+6.40%-3.16%-21.15%-26.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFOLDAmicus Therapeutics4.0149 of 5 stars3.42.00.04.31.70.01.9LGNDLigand Pharmaceuticals3.9802 of 5 stars2.50.00.04.42.63.31.9MNKDMannKind2.5905 of 5 stars3.61.00.00.01.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/AFOLDAmicus Therapeutics 2.70Moderate Buy$16.22184.10% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1423.62% UpsideMNKDMannKind 3.29Buy$10.33158.98% UpsideCurrent Analyst Ratings BreakdownLatest AVEO, LGND, FOLD, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.004/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28FOLDAmicus Therapeutics$528.29M3.33N/AN/A$0.65 per share8.78LGNDLigand Pharmaceuticals$167.13M13.64$1.65 per share71.55$43.95 per share2.69MNKDMannKind$285.50M4.25$0.15 per share27.34($0.29) per share-13.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AFOLDAmicus Therapeutics-$56.11M-$0.09N/A13.28N/A-5.41%4.67%1.05%8/14/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A31.87N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)MNKDMannKind$27.59M$0.1039.9017.35N/A10.12%-32.41%10.85%8/6/2025 (Estimated)Latest AVEO, LGND, FOLD, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35FOLDAmicus Therapeutics2.023.342.47LGNDLigand PharmaceuticalsN/A5.275.02MNKDMannKindN/A2.362.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%FOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals7.00%MNKDMannKind3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableMNKDMannKind400303.93 million294.82 millionOptionableAVEO, LGND, FOLD, and MNKD HeadlinesRecent News About These CompaniesLeerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy RatingJune 24 at 4:18 PM | insidermonkey.comMannKind Corporation (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from BrokeragesJune 24 at 3:01 AM | americanbankingnews.comMannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesJune 24 at 2:59 AM | marketbeat.comLeerink Partnrs Analysts Cut Earnings Estimates for MannKindJune 21, 2025 | americanbankingnews.comMannKind FY2026 EPS Forecast Decreased by Leerink PartnrsJune 19, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Reaches New 1-Year Low - Should You Sell?June 17, 2025 | marketbeat.comMannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical DataJune 16, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Buy" RatingJune 14, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of StockJune 11, 2025 | insidertrades.comInsider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)June 10, 2025 | gurufocus.comMannKind Co. (NASDAQ:MNKD) Director Sells 64,085 SharesJune 10, 2025 | marketbeat.comMannKind’s Strategic Growth Potential and Market Positioning: A Buy RecommendationJune 10, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?June 10, 2025 | marketbeat.comCantor Fitzgerald Estimates MannKind FY2026 EarningsJune 10, 2025 | marketbeat.comMannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock newsJune 9, 2025 | gurufocus.comMannKind Corporation to Showcase Inhaled Insulin Innovations at ADA's 85th Scientific SessionsJune 9, 2025 | quiverquant.comMannKind to present inhaled insulin study at ADA eventJune 9, 2025 | investing.comMannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23June 9, 2025 | globenewswire.comMannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street ZenJune 7, 2025 | marketbeat.com180 Wealth Advisors LLC Has $11.04 Million Holdings in MannKind Co. (NASDAQ:MNKD)June 2, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesMay 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVEO, LGND, FOLD, and MNKD Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Amicus Therapeutics NASDAQ:FOLD$5.71 0.00 (0.00%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$5.72 +0.01 (+0.19%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$118.22 +3.25 (+2.83%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$118.09 -0.13 (-0.11%) As of 06/24/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$3.99 +0.19 (+5.00%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$3.97 -0.02 (-0.53%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Insiders Chase Income and Stability in American Tower—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
